Concepts (79)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Crohn Disease | 3 | 2012 | 25 | 0.540 |
Why?
|
| Capsule Endoscopy | 1 | 2012 | 3 | 0.430 |
Why?
|
| Intestinal Diseases | 1 | 2012 | 18 | 0.430 |
Why?
|
| Intestine, Small | 1 | 2012 | 35 | 0.430 |
Why?
|
| Uvula | 1 | 2009 | 2 | 0.360 |
Why?
|
| Endoscopy, Digestive System | 1 | 2009 | 9 | 0.360 |
Why?
|
| Colitis, Ulcerative | 2 | 2006 | 20 | 0.350 |
Why?
|
| Lymphomatoid Papulosis | 1 | 2009 | 2 | 0.350 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2006 | 71 | 0.340 |
Why?
|
| Colonography, Computed Tomographic | 1 | 2008 | 10 | 0.330 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2009 | 91 | 0.320 |
Why?
|
| Early Detection of Cancer | 1 | 2008 | 75 | 0.310 |
Why?
|
| Antibodies, Monoclonal | 1 | 2009 | 197 | 0.300 |
Why?
|
| Skin Neoplasms | 1 | 2009 | 206 | 0.290 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2006 | 15 | 0.290 |
Why?
|
| Pyrazoles | 1 | 2006 | 65 | 0.280 |
Why?
|
| Sulfonamides | 1 | 2006 | 65 | 0.280 |
Why?
|
| Colorectal Neoplasms | 1 | 2008 | 208 | 0.280 |
Why?
|
| Esophagoscopy | 1 | 2005 | 19 | 0.260 |
Why?
|
| Esophageal Neoplasms | 1 | 2005 | 33 | 0.250 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2005 | 143 | 0.230 |
Why?
|
| Registries | 2 | 2019 | 280 | 0.210 |
Why?
|
| Adenocarcinoma | 1 | 2005 | 301 | 0.210 |
Why?
|
| Adult | 7 | 2019 | 8511 | 0.180 |
Why?
|
| Postpartum Period | 1 | 2019 | 29 | 0.170 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2019 | 23 | 0.170 |
Why?
|
| Preventive Health Services | 1 | 2019 | 31 | 0.170 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2019 | 32 | 0.170 |
Why?
|
| Retrospective Studies | 4 | 2012 | 3135 | 0.160 |
Why?
|
| Aged, 80 and over | 4 | 2012 | 3758 | 0.160 |
Why?
|
| Vaccination | 1 | 2019 | 126 | 0.150 |
Why?
|
| Male | 8 | 2012 | 17969 | 0.140 |
Why?
|
| Humans | 11 | 2019 | 29449 | 0.140 |
Why?
|
| Young Adult | 2 | 2012 | 2423 | 0.120 |
Why?
|
| Aged | 5 | 2012 | 9572 | 0.110 |
Why?
|
| Middle Aged | 5 | 2012 | 10920 | 0.110 |
Why?
|
| Duodenoscopy | 1 | 2012 | 2 | 0.110 |
Why?
|
| Gastroscopy | 1 | 2012 | 9 | 0.110 |
Why?
|
| Linoleic Acids, Conjugated | 1 | 2012 | 7 | 0.110 |
Why?
|
| Female | 6 | 2019 | 18341 | 0.100 |
Why?
|
| Necrosis | 1 | 2009 | 53 | 0.090 |
Why?
|
| Intestines | 1 | 2009 | 54 | 0.090 |
Why?
|
| Prospective Studies | 2 | 2019 | 2041 | 0.090 |
Why?
|
| Image Enhancement | 1 | 2009 | 70 | 0.090 |
Why?
|
| Pilot Projects | 2 | 2012 | 486 | 0.090 |
Why?
|
| Immunocompromised Host | 1 | 2009 | 43 | 0.090 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 2121 | 0.090 |
Why?
|
| Child, Preschool | 1 | 2012 | 1171 | 0.080 |
Why?
|
| Mesalamine | 1 | 2006 | 2 | 0.070 |
Why?
|
| Adolescent | 2 | 2012 | 3278 | 0.070 |
Why?
|
| Placebos | 1 | 2006 | 61 | 0.070 |
Why?
|
| Child | 1 | 2012 | 2228 | 0.070 |
Why?
|
| Early Diagnosis | 1 | 2005 | 62 | 0.060 |
Why?
|
| Abdominal Neoplasms | 1 | 2004 | 15 | 0.060 |
Why?
|
| Sex Distribution | 1 | 2005 | 188 | 0.060 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 2004 | 20 | 0.060 |
Why?
|
| Abdominal Wall | 1 | 2004 | 20 | 0.060 |
Why?
|
| Age Distribution | 1 | 2005 | 199 | 0.060 |
Why?
|
| Cohort Studies | 1 | 2008 | 1701 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2009 | 1221 | 0.060 |
Why?
|
| Neoplasm Staging | 1 | 2005 | 438 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 533 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2005 | 493 | 0.060 |
Why?
|
| Incidence | 1 | 2005 | 1126 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 2 | 2019 | 375 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2005 | 1327 | 0.040 |
Why?
|
| Patient Compliance | 1 | 2019 | 213 | 0.040 |
Why?
|
| Prognosis | 1 | 2019 | 1369 | 0.030 |
Why?
|
| Interleukin-17 | 1 | 2012 | 14 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2012 | 51 | 0.030 |
Why?
|
| Immunity | 1 | 2012 | 20 | 0.030 |
Why?
|
| PPAR gamma | 1 | 2012 | 45 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2012 | 47 | 0.030 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2012 | 50 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2012 | 172 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2012 | 93 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2012 | 200 | 0.020 |
Why?
|
| Quality of Life | 1 | 2012 | 828 | 0.020 |
Why?
|
| Guideline Adherence | 1 | 2006 | 111 | 0.020 |
Why?
|